Multifunctional Hypoxia-Involved Gene Silencing Nanoplatform for Sensitizing Photochemotherapy
Source abstract
Abstract
The integration of combinational photochemotherapy could achieve a promoted therapeutic performance by eliminating the frustrating side effects of each constitute, yet it is still confronted with severe therapeutic resistances that are associated with tumor hypoxia. Herein, we designed a multifunctional gene-therapy-promoted photochemotherapy strategy for specifically alleviating the hypoxia-associated therapeutic resistance. The pH-responsive zeolitic imidazolate framework-8 (ZIF-8) nanoparticles (CDHNs) facilitated the effective delivery of therapeutic agents (chlorin e6 (Ce6), doxorubicin (DOX), and HIF-1α siRNA) into the tumor for relieving specifically photochemotherapy resistance via sequential activation manners under the guidance of fluorescence imaging. The present all-in-one compact CDHNs system provides a smart and versatile multiply gained therapeutic strategy to activate the specific cellular pathways and is anticipated to boost future cancer diagnosis and post-treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, P. R. China
Key Laboratory of Biomedical Polymers (Ministry of Education), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, P. R. China
Funding
Ministry of Education of the People's Republic of China · National Natural Science Foundation of China
References (36)
Show source-provided references
1. 10.1002/advs.20160010610.1002/advs.201600106 ↗
2. 10.1002/adhm.20170121110.1002/adhm.201701211 ↗
3. 10.7150/thno.1498810.7150/thno.14988 ↗
4. 10.1021/nn305011p10.1021/nn305011p ↗
5. 10.1126/sciadv.aaz057510.1126/sciadv.aaz0575 ↗
6. 10.1038/ncomms462310.1038/ncomms4623 ↗
7. 10.1016/j.biomaterials.2016.11.05710.1016/j.biomaterials.2016.11.057 ↗
8. 10.1021/cr500419810.1021/cr5004198 ↗
9. 10.1021/acsnano.7b0303710.1021/acsnano.7b03037 ↗
10. 10.1021/ja400805b10.1021/ja400805b ↗
11. 10.1158/1541-7786.MCR-07-037710.1158/1541-7786.MCR-07-0377 ↗
12. 10.1021/acs.accounts.8b0021410.1021/acs.accounts.8b00214 ↗
13. 10.1002/adtp.20180002610.1002/adtp.201800026 ↗
14. 10.1021/acsnano.8b0359010.1021/acsnano.8b03590 ↗
15. 10.1021/acsami.9b1068510.1021/acsami.9b10685 ↗
16. 10.1038/ncomms178610.1038/ncomms1786 ↗
17. 10.1038/nrc300710.1038/nrc3007 ↗
18. 10.1038/nrc395810.1038/nrc3958 ↗
19. 10.1038/nrc306410.1038/nrc3064 ↗
20. 10.1002/adma.20180595510.1002/adma.201805955 ↗
21. 10.1073/pnas.090935310610.1073/pnas.0909353106 ↗
22. 10.1021/ml300463210.1021/ml3004632 ↗
23. 10.1002/anie.20130836810.1002/anie.201308368 ↗
24. 10.1021/mp300193f10.1021/mp300193f ↗
25. 10.1016/j.drudis.2018.01.04210.1016/j.drudis.2018.01.042 ↗
26. 10.1021/cr500131f10.1021/cr500131f ↗
27. 10.1002/adma.20160386410.1002/adma.201603864 ↗
28. 10.1021/acs.chemrev.5b0012510.1021/acs.chemrev.5b00125 ↗
29. 10.1021/jacs.9b0272610.1021/jacs.9b02726 ↗
30. 10.1002/smll.20160345910.1002/smll.201603459 ↗
31. 10.1021/acsnano.8b0341710.1021/acsnano.8b03417 ↗
32. 10.1021/cr500419810.1021/cr5004198 ↗
33. 10.1021/acs.nanolett.6b0434610.1021/acs.nanolett.6b04346 ↗
34. 10.1021/nn404407g10.1021/nn404407g ↗
35. 10.1002/mabi.20120023510.1002/mabi.201200235 ↗
36. 10.1126/sciadv.aau751810.1126/sciadv.aau7518 ↗